P2RX4

 

P2X receptors are composed of three subunits that can be homomeric or heteromeric by nature. In mammals, there are seven different subunits, each encoded in a different gene (P2RX1-P2RX7).^[5] Each subunit has two transmembrane alpha helices (TM1 and TM2) linked by a large extracellular loop.^[5][12][19] Analysis of x-ray crystallographic structures revealed a 'dolphin-like' tertiary structure, where the 'tail' is embedded in the phospholipid bilayer and the upper and lower ectodomains form the 'head' and 'body' respectively.^[12][19][20] Adjacent interfaces of the subunits form a deep binding pocket for ATP.^[12][19] ATP binding to these orthosteric sites causes a shift in conformation opening the channel pore.

The P2X₄ subunits can form homomeric or heteromeric receptors.^[21] In 2009, the first purinergic receptor crystallized was the closed state homomeric zebrafish P2X₄ receptor.^[22][19] Although truncated at its N- and C- termini, this crystal structure resolved and confirmed that these proteins were indeed trimers with an ectodomain rich with disulfide bonds.^[5][12]

 

P2X receptors have three confirmed conformational states: ATP-unbound closed, ATP-bound open, and ATP-bound desensitized.^[12][19] Imaging of the human P2X₃ and rat P2X₇ receptors has revealed structural similarities and differences in their cytoplasmic domains. In the ATP-bound state, both receptor types form beta sheet structures from N- and C- termini of adjacent subunits.^[12][19] These newly folded secondary structures come together to form a 'cytoplasmic cap' that helps stabilize the open pore. Crystal structures of the desensitized receptor no longer exhibit the cytoplasmic cap.^[12][19]

Electrophysiology studies have revealed differences in the rates of receptor desensitization between different P2X subtypes.^[5][12] Homotrimers P2X₁ and P2X₃ are the fastest, with desensitization observed milliseconds after activation, while P2X₂ and P2X₄ receptors are on the timescale of seconds. Notably, the P2X₇ receptor uniquely does not undergo desensitization.^[12] Mutational studies working with the rat P2X₂ and P2X₃ receptors have identified three residues in the N-terminus that majorly contribute to these differences. By changing the amino acids in the P2X₃ to match the analogous P2X₂, the desensitization rate slowed down. Conversely, changing residues of P2X₂ to match P2X₃ increased the desensitization rate.^[19] In combination with the open state crystal structures, it was hypothesized that the cytoplasmic cap was stabilizing the open pore conformation.^[12][19]

Additionally, structural analysis of the open P2X₃ receptor revealed transient changes in TM2, the transmembrane alpha helix lining the pore. While in the open state conformation, a small mid-region of TM2 develops into a 3₁₀-helix.^[12][19] This helical structure disappears with desensitization and instead TM2 reforms as a complete alpha helix repositioned closer to the extracellular side.^[12]

The helical recoil model uses the observed structural changes in TM2 and the transient formation of the cytoplasmic cap to describe a possible mechanism for the desensitization of P2X receptors. In this model, it is theorized that the cytoplasmic cap fixes the intracellular end of the TM2 helix while stretching its extracellular end to allow ion influx.^[19] This would induce the observed 3₁₀-helix. The cap then disassembles and releases its hold on TM2 causing the helix to recoil towards the outer leaflet of the membrane.^[12][19]

In support of this theory, the P2X₇ uniquely has a large cytoplasmic domain with palmitoylated C-cysteine anchor sites.^[5][12][19] These sites further stabilize its cytoplasmic cap by anchoring the domain into the surrounding inner leaflet. Mutations of the associated palmitoylation site residues cause observed atypical desensitization of the receptor.^[12]

P2X₄ receptors are functionally expressed on both the cell surface and in lysosomes.^[20] Although preferentially localized and stored in lysosomes, P2X₄ receptors are brought to the cell surface in response to extracellular signals.^[23] These signals include IFN-γ, CCL21, CCL2.^[24][25][26] Fibronectin is also involved in upregulation of P2X₄ receptors through interactions with integrins that lead to the activation of SRC-family kinase member, Lyn.^[27] Lyn then activates PI3K-AKT and MEK-ERK signaling pathways to stimulate receptor trafficking.^[28] Internalization of P2X₄ receptors is clathrin- and dynamin-dependent endocytosis.^[29]

P2X₄ receptors respond to ATP, but not αβmeATP. These receptors are also potentiated by ivermectin, cibacron blue, and zinc.^[8]

The main pharmacological distinction between the members of the purinoceptor family is the relative sensitivity to the antagonists suramin and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS). The product of this gene has the lowest sensitivity for these antagonists^[8]

The P2X₄ receptor has been linked to neuropathic pain mediated by microglia in vitro and in vivo.^[30][31] P2X₄ receptors are upregulated following injury.^[32] This upregulation allows for increased activation of p38 mitogen-activated protein kinases, thereby increasing the release of brain-derived neurotrophic factor (BDNF) from microglia.^[33] BDNF released from microglia induces neuronal hyperexcitability through interaction with the TrkB receptor.^[34] More importantly, recent work shows that P2X₄ receptor activation is not only necessary for neuropathic pain, but it is also sufficient to cause neuropathic pain.^[35]

• P2X receptor

• P2RX4+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.